Sai Parenterals Limited is stepping up its push into India’s prescription pharmaceutical market, with its wholly owned subsidiary, SP Analytics Private Limited, signing a definitive agreement to acquire a majority stake in Hyderabad-based Bion Therapeutics India Private Limited.
The all-cash deal, expected to close before the end of November, will bring 16 established branded formulations, a 250-member field force and an extensive doctor and retail network into the Sai Parenterals fold. Upon completion, Bion Therapeutics will become a step-down subsidiary of Sai Parenterals.
Founded in 2005, Bion Therapeutics has built its prescription business around niche therapeutic segments, including neuropathy, diabetes supportive care, mitochondrial health, wound care and pain management. Its portfolio includes 16 brands, with Meaxon, MITOQ7, Adgaba, Sunlite and LG Bion among its key products.
The acquisition gives Sai Parenterals immediate access to a well-established prescription sales network spanning 12 states, approximately 20,000 doctors and more than 17,000 retailers. Bion's 250-strong field team, backed by nearly two decades of doctor engagement and specialty-focused marketing, is expected to provide the platform for a significant expansion of Sai Parenterals' domestic branded formulations business.
The deal also brings together complementary strengths in manufacturing, research and market access.
Sai Parenterals, which recently acquired Sai Prathyak Laboratories, has an in-house R&D centre with a portfolio of 174 molecules and 285 stock-keeping units (SKUs). The addition of Bion's established field network gives the company a direct route to take its expanding product pipeline to doctors and the prescription market.
On the manufacturing front, Sai Parenterals plans to progressively shift Bion's products from third-party contract manufacturers to its own facilities, which hold TGA-Australia and WHO-GMP accreditations. The move is expected to strengthen supply reliability, improve quality control and enhance margins.
The acquisition will also open up opportunities to expand Bion's product basket. Selected molecules from Noumed's library of more than 511 TGA-approved dossiers could be introduced to Indian doctors under Bion brands, subject to regulatory approvals in India.
In another strategic opportunity, Sai Parenterals' SAICRITI critical-care injectable facility at Gummadidala, scheduled for completion in August 2027, is expected to provide an entry route for Bion's injectable portfolio, led by Meaxon, into the hospital and critical-care segments.
Bion's existing management team will continue to lead the business after the acquisition, ensuring continuity in its doctor relationships and market operations.
The transaction will be funded through internal accruals, debt and a portion of the general corporate purposes allocation from Sai Parenterals' initial public offering proceeds. The company said further details of the transaction would be disclosed at the appropriate stage.
Commenting on the agreement, Anil Kumar Karusala, Chairman and Managing Director, Sai Parenterals Limited, said: "India’s branded formulations market rewards two things above all: brands that doctors trust, and a field organisation disciplined enough to sustain that trust over time.
"Bion has built both over nearly two decades, power brands led by Meaxon and MITO Q7 Plus, a presence across twelve states and a field organisation of two hundred and fifty people engaging with twenty thousand doctors. A franchise of this nature is established over many years, and it comes to us intact, the brands, the relationships and the organisation that sustains them."
He added: "This acquisition completes the platform we have been building. Over the past year we have expanded capacity at Unit III, begun construction of the critical-care injectable facility at Gummadidala, consolidated all our research at Sai Prathyak, and strengthened the Noumed platform in Australia and New Zealand.
"Each of these strengthens what we are able to develop and manufacture. Bion provides the route to take them to the Indian market directly, converting development capability into branded revenue.
"The value flows in both directions. Bion’s portfolio, presently manufactured by third parties, will transfer to our accredited facilities, improving supply assurance, quality control and margin. In turn, our development pipeline and Noumed’s dossier library give Bion’s field organisation a materially wider portfolio to take to market. We will disclose the further particulars of the transaction at the appropriate stage.”
Laxman Prasad Shukla, Managing Director, Bion Therapeutics India Private Limited, said: “Bion’s brands have been built on clinical credibility and sustained engagement with the medical community. Our therapeutic focus, neuropathy, diabetes supportive care, mitochondrial health, wound care and pain management has allowed us to establish depth in the segments that matter to us, rather than breadth for its own sake.
"Joining the Sai Parenterals Group addresses the constraint we have felt most acutely: access to manufacturing depth and a development pipeline at the scale our market position warrants. Our team will continue to lead the business and its relationships. What changes is the breadth of the portfolio they are able to take to market.”